Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: An international phase II study in patients requiring treatment according to GELF/BNLI criteria

Journal of Clinical Oncology

Volumn 32, Issue 3, 2014, Pages 212-218

  Illidge, Tim M ^a   Mayes, Sam ^a   Pettengell, Ruth ^c   Bates, Andrew T ^d   Bayne, Mike ^e   Radford, John A ^a   Ryder, W David J ^a   Le Gouill, Steven ^f   Jardin, Fabrice ^h   Tipping, Jill ^b   Zivanovic, Maureen ^b   Kraeber Bodere, Françoise ^f   Bardies, Manuel ⁱ   Bodet Milin, Caroline ^f   Malek, Emmanuel ^g   Huglo, Damien ^g   Morschhauser, Franck ^g  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB; MONOCLONAL ANTIBODY; YTTRIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW BIOPSY; BONE MARROW TOXICITY; BREAST METASTASIS; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER RADIOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; LARGE CELL LYMPHOMA; LETHARGY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOTHERAPY; RASH; REPEAT PROCEDURE; SALVAGE THERAPY; SECOND CANCER; SKIN TOXICITY; THROMBOCYTOPENIA; TUMOR BIOPSY; INTERNATIONAL COOPERATION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DOSE FRACTIONATION; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84897019975     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.3110     Document Type: Article

References (30)

1. Ansell SM, Armitage J: Non-Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc 80:1087-1097, 2005 (Pubitemid 41099397)
2. Herold M, Dölken G, Fiedler F, et al: Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: Chemotherapy versus chemotherapy plus rituximab. Ann Hematol 82:77-79, 2003 (Pubitemid 36700978)
3. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
4. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
5. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013
6. Fisher RI, Kaminski MS, Wahl RL, et al: Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 23:7565-7573, 2005 (Pubitemid 46291820)
7. Gordon LI, Molina A, Witzig T, et al: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004 (Pubitemid 38745967)
8. Wiseman GA, Witzig TE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 20:185-188, 2005 (Pubitemid 40696100)
9. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
10. Kennel SJ: Effects of target antigen competition on distribution of monoclonal antibody to solid tumors. Cancer Res 52:1284-1290, 1992
11. Schlom J, Molinolo A, Simpson JF, et al: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82:763-771, 1990 (Pubitemid 20159276)
12. DeNardo GL, Schlom J, Buchsbaum DJ, et al: Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94:1332-1348, 2002 (Pubitemid 34150897)
13. Illidge TM, Bayne M, Brown NS, et al: Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113:1412-1421, 2009
14. Ferrer L, Malek E, Bodet-Milin C, et al: Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. Q J Nucl Med Mol Imaging 56:529-537, 2012
15. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
16. US National Institutes of Health. CTCAE/CTC Archive. http://ctep.cancer. gov/protocolDevelopment/electronic-applications/ctc.htm#ctc-archive
17. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
18. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed nonhodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003 (Pubitemid 46606402)
19. Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005 (Pubitemid 40175970)
20. Connors JM: Radioimmunotherapy: Hot new treatment for lymphoma. N Engl J Med 352:496-498, 2005
21. Scholz CW, Pinto A, Linkesch W, et al: 90Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 31:308-313, 2013
22. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
23. Witzig TE, Molina A, Gordon LI, et al: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109:1804-1810, 2007 (Pubitemid 46668544)
24. Emmanouilides C, Witzig TE, Gordon LI, et al: Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 47:629-636, 2006
25. Wiseman GA, Gordon LI, Multani PS, et al: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 99:4336-4342, 2002 (Pubitemid 34627198)
26. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002 (Pubitemid 34525730)
27. Lillington DM, Micallef IN, Carpenter E, et al: Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol 19:2472-2481, 2001 (Pubitemid 32391218)
28. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 17:3128-3135, 1999 (Pubitemid 29470642)
29. Czuczman MS, Emmanouilides C, Darif M, et al: Analysis of the incidence of treatment-related myelodysplastic syndrome and acute myelogenous leukemia in registration and compassionate-use trials of ibritumomab tiuxetan radioimmunotherapy (RIT). ASH Annual Meeting Abstracts 108:485, 2006
30. Morschhauser F, Radford J, Van Hoof A, et al: 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 7.3 years from the international, randomized, phase III firstline indolent trial. J Clin Oncol 31:1977-1983, 2013